Skip to main navigation Skip to search Skip to main content

The association between proton pump inhibitors and the risk of gastrointestinal bleeding in oral anticoagulants users

  • Zixuan Wang
  • , Qiuyan Yu
  • , Charlotte Warren-Gash
  • , Krishnan Bhaskaran
  • , Clémence Leyrat
  • , Ka Shing Cheung
  • , Celine S. L. Chui
  • , Esther W. Chan
  • , Ian C. K. Wong
  • , Amitava Banerjee
  • , Liam Smeeth
  • , Ian J. Douglas
  • , Angel Y. S. Wong*
  • *Corresponding author for this work
    • The University of Hong Kong, Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, Hong Kong SAR, China, ROR: https://ror.org/02zhqgq86, GRID: grid.194645.b, ISNI: 0000 0001 2174 2757
    • London School of Hygiene and Tropical Medicine, Faculty of Epidemiology and Population Health, London, United Kingdom, ROR: https://ror.org/00a0jsq62, GRID: grid.8991.9, ISNI: 0000 0004 0425 469X
    • The University of Hong Kong, School of Public Health, Li Ka Shing, Faculty of Medicine, Hong Kong, China, ROR: https://ror.org/02zhqgq86, GRID: grid.194645.b, ISNI: 0000 0001 2174 2757

    Research output: Contribution to journalArticlepeer-review

    9 Downloads (Pure)

    Abstract

    Current evidence of whether proton pump inhibitor (PPI) reduces the risk of gastrointestinal bleeding (GIB) associated with oral anticoagulants (OACs) is limited. Propensity score-weighted cohort and case-crossover studies were conducted separately in England and Hong Kong between 2011.01.01 and 2019.12.31. In the cohort design, we compared the hazards of hospitalised GIB in OAC + PPI users with OAC only users in people with atrial fibrillation and found higher hazard of GIB in OAC + PPI users in both settings. In the case-crossover design, elevated odds of exposure to PPI only, OAC only and OAC + PPI associated with GIB between 30-day hazard and referent periods were similarly found in both settings. Overall, the evidence of an elevated risk of OAC + PPI associated with GIB compared with OAC only was modest in the cohort study. Our case-crossover study suggested that residual confounding is likely to explain the association, suggesting that concomitant prescription of PPI with OAC did not modify GIB.
    Original languageEnglish
    Article number11
    Number of pages11
    Journalnpj Cardiovascular Health
    Volume2
    Issue number1
    Early online date12 Apr 2025
    DOIs
    Publication statusPublished - 12 Apr 2025

    Bibliographical note

    Copyright © The Author(s) 2025. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted
    by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/

    Data Access Statement

    Computing code and study protocol are available from the corresponding author upon request for reproducing the results. However, the study data cannot be made available to other researchers because of the terms specified in Data Use Agreements.

    Funding

    This work was supported by the British Heart Foundation (FS/19/19/34175) and the Laboratory of Data Discovery for Health (D24H) funded by AIR@InnoHK administered by Innovation and Technology Commission, the Government of the Hong Kong Special Administrative Region, China. L.S. reports grants from Wellcome, MRC, NIHR, UKRI, British Council, GSK, British Heart Foundation, and Diabetes UK outside this work. I.D. holds grants from NIHR, GSK and AIR@InnoHK administered by Innovation and Technology Commission. C.L. is supported by the UK Medical Research Council (Skills Development Fellowship MR/T032448/1). C.W.G. is funded by a Wellcome Career Development Award (225868/Z/22/Z). K.B. is funded by a Wellcome Senior Research Fellowship (220283/Z/20/Z).

    Fingerprint

    Dive into the research topics of 'The association between proton pump inhibitors and the risk of gastrointestinal bleeding in oral anticoagulants users'. Together they form a unique fingerprint.

    Cite this